Gilder Gagnon Howe & Co. LLC Increases Holdings in Kymera Therapeutics, Inc. $KYMR

Gilder Gagnon Howe & Co. LLC lifted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 3.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 329,020 shares of the company’s stock after acquiring an additional 10,639 shares during the period. Gilder Gagnon Howe & Co. LLC owned 0.46% of Kymera Therapeutics worth $14,358,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KYMR. Farther Finance Advisors LLC lifted its holdings in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after purchasing an additional 540 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Kymera Therapeutics during the second quarter valued at approximately $73,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics in the first quarter worth $68,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Kymera Therapeutics by 15.8% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company’s stock worth $110,000 after acquiring an additional 343 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Royal Bank Of Canada began coverage on shares of Kymera Therapeutics in a report on Tuesday, September 16th. They issued an “outperform” rating and a $70.00 price target on the stock. Citigroup increased their price objective on shares of Kymera Therapeutics from $80.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday. BTIG Research set a $138.00 target price on Kymera Therapeutics in a report on Monday. Truist Financial boosted their target price on Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Oppenheimer increased their price target on Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Kymera Therapeutics has a consensus rating of “Buy” and an average target price of $112.80.

Insider Transactions at Kymera Therapeutics

In other news, insider Jared Gollob sold 59,576 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $61.42, for a total transaction of $3,659,157.92. Following the transaction, the insider owned 109,992 shares of the company’s stock, valued at approximately $6,755,708.64. The trade was a 35.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Bruce N. Jacobs sold 79,220 shares of the firm’s stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.00, for a total value of $3,961,000.00. Following the completion of the sale, the chief financial officer owned 227,409 shares of the company’s stock, valued at approximately $11,370,450. This represents a 25.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 597,805 shares of company stock worth $46,839,199. 16.01% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Stock Up 2.1%

Kymera Therapeutics stock opened at $89.68 on Friday. The company’s 50-day moving average price is $64.77 and its 200-day moving average price is $51.85. The company has a market cap of $6.45 billion, a PE ratio of -24.98 and a beta of 2.28. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The business had revenue of $2.76 million during the quarter, compared to the consensus estimate of $23.15 million. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.